Why should women up to age 29 be screened for high-risk human papillomavirus (HPV) during Pap testing?

Why HPV Screening Should NOT Be Done During Paps Until Age 29

HPV testing should not be used for routine cervical cancer screening in women aged 21-29 years because HPV infections are extremely common and usually transient in this age group, leading to unnecessary colposcopies and overtreatment of lesions that would spontaneously regress. 1, 2, 1

The Core Problem: High HPV Prevalence with Low Cancer Risk

In women under 30, HPV infection rates can reach 36.8-43% 3, 4, yet the overwhelming majority of these infections clear spontaneously without ever causing cervical cancer. The average time for a high-grade precancerous lesion to progress to invasive cancer is approximately 10 years 5, meaning that even if a young woman develops a precancerous lesion, there is ample time to detect it through cytology alone before it becomes dangerous.

Age-Specific Screening Recommendations

Ages 21-24 Years

• Screen with cytology alone every 3 years 2, 1
• HPV testing is explicitly not recommended for routine screening 2, 1
• Reflex HPV testing is acceptable only for ASC-US results, but repeat cytology is preferred 1
• Conservative management is strongly recommended to avoid overtreatment 1

Ages 25-29 Years

• Continue cytology alone every 3 years 2, 1
• Cotesting (cytology + HPV) is not recommended for routine screening 1
• However, reflex HPV testing is preferred (not routine screening) for managing abnormal cytology results of ASC-US, because cervical cancer risk begins to increase in this age group 1

Ages 30-65 Years

• Cotesting every 5 years is preferred, or cytology alone every 3 years is acceptable 2, 1
• This is when routine HPV testing becomes appropriate

Why This Approach Makes Sense

The rationale is straightforward: using HPV testing in women under 30 would result in:

1. Excessive colposcopy referrals: With HPV positivity rates of 21.9% in 25-29 year-olds 6, versus only 10% with cytology alone, you'd be referring twice as many young women for invasive procedures

2. Detection of clinically insignificant disease: Most HPV infections and even low-grade lesions in young women regress without treatment 1

3. Risk of overtreatment: Treatment of cervical lesions can cause pregnancy complications, including preterm birth and cervical insufficiency—particularly problematic in women who haven't completed childbearing 1

4. Poor specificity despite high sensitivity: While HPV testing is more sensitive than cytology, this increased sensitivity in young women primarily detects transient infections rather than true cancer precursors 6

The Exception: Managing Abnormal Results

The guidelines do allow HPV testing in women aged 25-29 years, but only as a reflex test (not routine screening) when cytology shows ASC-US 1. This is because:

• It helps triage which women with equivocal cytology need colposcopy
• Cervical cancer risk genuinely begins increasing after age 25 1
• It reduces unnecessary repeat visits compared to repeat cytology alone

Common Pitfalls to Avoid

1. Don't order routine HPV testing just because it's available: The 2010 CDC guidelines explicitly state HPV testing should not be used for women under 20 years for screening or management 7

2. Don't confuse reflex testing with routine screening: Reflex HPV testing after abnormal cytology is different from cotesting at the initial screening visit

3. Don't screen annually: No woman of any age should be screened more frequently than every 3 years 2, 1

Recent Evidence Considerations

While one 2026 study 3 suggested potential benefits of earlier HPV screening, and another 8 proposed screening for persistent HPV infections in younger women, these represent emerging research that has not yet been incorporated into major society guidelines. The most recent comprehensive guideline update from 2020 9 maintained the recommendation against routine HPV testing before age 30, though it did lower the age for primary HPV screening to 25 years when used as the screening modality (not cotesting).

The current standard remains: cytology alone every 3 years for women aged 21-29 years, with HPV testing reserved for managing abnormal results in women aged 25-29 years. 2, 1, 9